drugset / Trial / NCT01452334
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the side effects of treatment with the monoclonal antibody anti-PD-L1 (BMS-936559) in subjects with compromised bone marrow function and the dose that should be recommended for use in future studies.
Timeline
- Start
- 2011-11
- Primary completion
- 2014-11
- Completion
- 2014-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-936559 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | BMS-936559 | Monoclonal antibody | 10 mg/kg | Intravenous |